IMR Press / CEOG / Volume 40 / Issue 1 / pii/1630388019123-1720988646

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Origianal Research
Adding luteinizing hormone to follicle stimulating hormone from day 3-5 improves pregnancy outcome in normal but not poor responders using gonadotropin releasing hormone antagonists
Show Less
1 Cooper Medical School of Rowan University, Department of Obstetrics and Gynecology Division of Reproductive Endocrinology and Infertility, Camden, NJ (USA)
Clin. Exp. Obstet. Gynecol. 2013, 40(1), 24–26;
Published: 10 March 2013
Abstract

Purpose: To determine if the addition of luteinizing hormone (LH) to follicle stimulating hormone (FSH) stimulation for controlled ovarian hyperstimulation (COH) protocols using gonadotropin releasing hormone (GnRH) antagonists improves pregnancy rates following in vitro fertilization-embryo transfer (IVF-ET). Materials and Methods: All IVF-ET cycles using a GnRH antagonist were evaluated according to whether FSH was used exclusively or if LH was added. The cycles were further stratified according to age (≤ 39 and 40-42 years) and according to good responders (≥ five oocytes retrieved) or poor responders (≤ four oocytes). Results: Combining all data, a significantly higher clinical and live delivered pregnancy rates were found in those adding LH (34.7% and 32.3%) vs those taking all FSH (33.4% and 25.8%). The only subgroup not showing this effect was the women aged 40-42 years with diminished oocyte reserve. Conclusions: LH should be added not only to COH protocols using GnRH agonists but also those using GnRH antagonists.
Keywords
Luteinizing hormone
Follicle stimulating hormone
Gonadotropin releasing hormone antagonist
In vitro fertilizationembryotransfer
Share
Back to top